A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease
NCT ID: NCT03246399
Last Updated: 2019-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
6 participants
INTERVENTIONAL
2017-07-26
2018-12-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration
NCT01124006
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
NCT01290367
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration
NCT03347708
Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration
NCT02379689
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.03mg SM04690
0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
SM04690
suspension formulation of SM04690, delivered via intradiscal injection (single injection)
0.07mg SM04690
0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
SM04690
suspension formulation of SM04690, delivered via intradiscal injection (single injection)
0.15mg SM04690
0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
SM04690
suspension formulation of SM04690, delivered via intradiscal injection (single injection)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SM04690
suspension formulation of SM04690, delivered via intradiscal injection (single injection)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persistent low back pain due to DDD for at least 3 months prior to study start
* Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
* Subjects must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed
Exclusion Criteria
* Women of child bearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period
* Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized or whom are not using a highly effective method of birth control
* Body mass index (BMI) \> 35
* Previous participation in a Samumed clinical trial investigating SM04690
* History of compression fractures and/or osteoporosis
* Any herniation in the lumbar spine as identified by MRI
* Congenital or acquired diseases leading to spine deformations
* History of hypersensitivity or allergies to any ingredient of the study medication
* Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure, or an observational research trial related to DDD within 8 weeks prior to any study injection, or planned participation in any such trial; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 8 weeks prior to study start
* Poor peripheral venous access
* Any contraindications to MRI according to MRI guidelines
* History of malignancy; however, subjects with prior history of in situ cancer or basal or squamous cell skin cancer, completely cured, are eligible.
* Any diagnosed psychiatric condition that includes, but is not limited to, a history of mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder
* Prior surgical procedures (e.g., discectomy, intradiscal electrothermal therapy, intradiscal radiofrequency, artificial disc replacement, and interbody fusion) on the lumbar spine
* Any planned or elective surgery during the study period
* Any known active infections, including hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV)
* Current or prior history of any spinal infection (i.e., discitis, septic arthritis, or epidural abscess)
* Any lumbar intradiscal injection procedure (e.g., injection of corticosteroids, methylene blue, dextrose, etc.), myelograms, discography, and/or lumbar epidural or transforaminal injections with corticosteroids or nerve-blocking anesthetics (e.g, lidocaine, bupivacaine) within 3 months prior to study start
* Any electrotherapy (i.e., transcutaneous electrical nerve stimulation \[TENS\] unit) or acupuncture for DDD within 4 weeks prior to study medication injection
* History of or current/pending disability claim, workers' compensation, or litigation(s) related to back pain/injury
* Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at any investigative site, or are directly affiliated with the study at any investigative site
* Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study, or who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of said employees responsible for the conduct of the study
25 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biosplice Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yusuf Yazici, M.D.
Role: STUDY_DIRECTOR
Biosplice Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
San Diego, California, United States
Research Site
Charleston, South Carolina, United States
Research Site
Tyler, Texas, United States
Research Site
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SM04690-DDD-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.